Overview
Addressing Today’s Challenging Bacterial Infections – Expert Views on Treatment Paradigms
Complimentary Lunch Symposium Preceding IDWeek 2018
Registration is closed for this activity.
This symposium will provide lively discussion and expert clinical analysis of the latest clinical data and therapeutic paradigms for treating two major types of refractory bacterial infections: Gram-negative pseudomonas and C. difficile infections, among others. New clinical practice guidelines from IDSA/SHEA and clinical best practices for optimal treatment of these challenging clinical situations will be discussed by experts in the infectious disease field, within the wider clinical context of responsible antimicrobial stewardship. Two complex patient infection cases (including a recorded patient testimonial from a C. difficile patient) will be presented for expert panel discussion and audience questions.
This activity is intended for ID specialists, gastroenterologists, hospitalists, pulmonologists, critical care specialists, internists, and other physicians, pharmacists, nurse practitioners, and physician assistants who care for patients at risk of serious infection.
The purpose of this activity is to update physicians and pharmacists that may come in clinical contact with serious, treatment-refractory bacterial infections such as C. difficile and Gram-negative infections with the latest clinical evidence, practice guidelines, and antimicrobial stewardship protocols for providing optimal treatment.
ACCME Learning Objectives:
• Demonstrate an understanding of the molecular epidemiology of antibiotic resistance in bacterial pathogens.
• Summarize the salient features and critical differences between novel antibiotics for use against Gram-negative pathogens.
• Describe clinical strategies to optimize antimicrobial therapy to ensure effectiveness of antibiotics and reduce resistance.
• Outline patient and clinical factors that may predict C. difficile recurrence and implement effective tools/processes to identify at-risk patients.
• Compare and contrast evidence-based approaches for the management of first and second recurrences of C. difficile infection in diverse patient populations, and appropriate targeted therapeutic selections for each.
• Discuss newly released IDSA/SHEA clinical practice guidelines for C. difficile infection and how they compare with established practice patterns.
• Demonstrate an understanding of the molecular epidemiology of antibiotic resistance in bacterial pathogens.
• Summarize the salient features and critical differences between novel antibiotics for use against Gram-negative pathogens.
• Describe clinical strategies to optimize antimicrobial therapy to ensure effectiveness of antibiotics and reduce resistance.
• Outline patient and clinical factors that may predict C. difficile recurrence and implement effective tools/processes to identify at-risk patients.
• Compare and contrast evidence-based approaches for the management of first and second recurrences of C. difficile infection in diverse patient populations, and appropriate targeted therapeutic selections for each.
• Discuss newly released IDSA/SHEA clinical practice guidelines for C. difficile infection and how they compare with established practice patterns.
ACPE Learning Objectives:
• Demonstrate an understanding of appropriate antimicrobial stewardship in the context of increased resistance in high-risk bacterial pathogens.
• Summarize the pharmacokinetics and spectrums of activity of novel antibiotics for use against Gram-negative pathogens versus established therapies.
• Describe clinical strategies to implement current pharmacy best practices to ensure effectiveness of antibiotics and reduce resistance in Gram-negative pathogens.
• Outline patient and clinical factors that may predict C. difficile recurrence and implement effective tools/processes to identify at-risk patients.
• Compare and contrast evidence-based approaches for medication therapy management (MTM) of first and second recurrences of C. difficile infection.
• Discuss newly released IDSA/SHEA clinical practice guidelines for C. difficile infection and how they may affect existing antimicrobial stewardship protocols.
Moscone Center
747 Howard St.
Moscone South 155 (Upper Mezzanine, Esplanade Ballroom)
San Francisco, CA 94103 USA
Click here to view location map
747 Howard St.
Moscone South 155 (Upper Mezzanine, Esplanade Ballroom)
San Francisco, CA 94103 USA
Click here to view location map
Supported by an educational grant from Merck & Company.
Onsite registration will begin at 11:00 AM on Wednesday, October 3rd in the Moscone South 155 meeting room. Please arrive early as space is limited.
Please call (877) 444-8435, ext. 203 prior to your arrival if you have special needs.
Please call (877) 444-8435, ext. 203 prior to your arrival if you have special needs.
James Lewis, II, PharmD, FIDSA Infectious Disease Clinical Pharmacy Supervisor Co-Director of Antibiotic Stewardship Department of Pharmacy Oregon Health & Science University Portland, OR | |
Sahil Khanna, MBBS Assistant Professor of Medicine Division of Gastroenterology and Hepatology Mayo Clinic Rochester, MN | |
James McKinnell, MD Assistant Professor of Medicine David Geffen School of Medicine University of California, Los Angeles Infectious Disease Clinical Outcome Research Unit Los Angeles Biomedical Research Institute at Harbor-UCLA Torrance, CA | |
Carlene Muto, MD, MS Associate Professor Department of Medicine, Infectious Diseases University of Virginia Charlottesville, VA |
In collaboration with: Kathy, a CDI patient and survivor of eight recurrences.
Guidelines require that participants in CME/CE activities be made aware of all financial relationships that may be perceived as affecting the presentation of the faculty member. ACHL ensures that all faculty and staff involved in the planning, development, and implementation of ACHL activities disclose relevant financial relationships and that conflicts of interest are resolved before the CME/CE activity occurs. Complete information will be provided to participants prior to the start of the educational activity.
This activity will take 90 minutes to complete. To receive credit, participants are required to participate in the live activity, complete the posttest and evaluation, and submit on-site. A certificate will be emailed to participants within 6 weeks. There is no fee to participate in the activity or for the generation of the certificate.
Inquiries may be directed to ACHL at (877) 444-8435, ext. 160.
CPE credit will be submitted to CPE Monitor® on the first day of each month.
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
The Academy for Continued Healthcare Learning designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
This activity has been approved for 1.5 contact hours.
ACPE Universal Activity Number: 0396-0000-18-048-L01-P
Activity Type: Knowledge